Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Advanced Cancer × LY2584702 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Cancer 1

Interventions

Nivolumab 4 Ipilimumab 3 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 tilsotolimod 1 relatlimab 1 linrodostat 1 Surveys and Questionnaires 1 Paclitaxel 1 LY2584702 1 EC145 1 Dasatinib 1 Chlorogenic Acid 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01394003 2019-01-18

A Study of LY2584702 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Terminated

34 enrolled 18 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡